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Abstract
Objectives: The relative roles of liver resection (LR) and liver transplantation (LT) in the treatment of a
solitary hepatocellular carcinoma (HCC) remain unclear. This study was conducted to provide a retro-
spective intention-to-treat comparison of these two curative therapies.
Methods: Records maintained at the study centre for all patients treated with LR or listed for LT for
hepatitis C-associated HCC between January 2002 and December 2007 were reviewed. Inclusion criteria
required: (i) an initial diagnosis of a solitary HCC lesion measuring  5 cm, and (ii) Child–Pugh class A or
B cirrhosis. The primary endpoint analysed was intention-to-treat survival.
Results: A total of 75 patients were listed for transplant (LT-listed group) and 56 were resected (LR
group). Of the 75 LT-listed patients, 23 (30.7%) were never transplanted because they were either
removed from the waiting list (n = 13) or died (n = 10). Intention-to-treat median survival was superior in
the LR group compared with the LT-listed group (61.8 months vs. 30.6 months), but the difference did not
reach significance. Five-year recurrence was higher in the LR group than in the 52 LT patients (71.5% vs.
30.5%; P < 0.001).
Conclusions: In the context of limited donor organ availability, partial hepatectomy represents an
efficacious primary approach in properly selected patients with hepatitis C-associated HCC.
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Introduction
For patients with solitary hepatocellular carcinoma (HCC) and
preserved liver function, partial hepatectomy is often considered
the treatment of choice. With careful patient selection and
modern surgical techniques, resection can be accomplished with
low operative mortality1–3 and can achieve 5-year survival rates
in the range of 61–78%.4–8 Nevertheless, intrahepatic recurrence
affects over 50% of patients at 5 years6,8–10 and relates to both
unrecognized intrahepatic dissemination and multicentric
carcinogenesis.
Total hepatectomy with liver transplantation (LT) eliminates
both unrecognized intrahepatic dissemination and the underlying
parenchymal disease that drives neocarcinogenesis. Since patient
selection strategies were refined according to the Milan Criteria to
include only patients with either one tumour measuring  5 cm
or up to three tumours all measuring < 3 cm,11 many groups have
reported dramatically improved recurrence and survival rates fol-
lowing transplant.12–15 However, as a result of donor organ scar-
city, many patients placed on the transplant waiting list do not
undergo transplantation because they are subject to either tumour
progression or hepatic decompensation. As a result, survival rates
fall when outcomes are analysed on an intention-to-treat basis.16
The nature of the underlying liver disease is an important con-
sideration in a comparison of resection and transplantation. In
the USA, as in Western Europe and Japan, hepatitis C is the most
common disease underlying HCC development.17,18 Survival after
either resection or transplantation is lower in patients with HCC
in the setting of hepatitis C compared with patients with HCC of
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other aetiologies. Hepatitis C virus (HCV) infection is an inde-
pendent predictor of local failure and impaired survival following
HCC resection,19–21 and recurrent hepatitis C after transplantation
may lead to accelerated parenchymal injury, fibrosis and graft
failure.22–25
This study provides an intention-to-treat comparison of resec-
tion and transplantation as primary curative therapies of solitary
hepatitis C-associated HCC measuring  5 cm.
Materials and methods
Patient selection and study design
The study was approved by the Mount Sinai Medical Center Insti-
tutional Review Board. Subsequently, records for all patients with
documented HCV-associated HCC (HCV-HCC) listed at the
Recanati/Miller Transplantation Institute, Mount Sinai Medical
Center and the Division of Surgical Oncology, Department of
Surgery, Mount Sinai Medical Center, New York, who were either
treated with partial hepatectomy or listed for orthotopic LT
between January 2002 and December 2007 were retrospectively
reviewed. Criteria for inclusion in the study required: (i) an initial
radiographic diagnosis of a solitary HCC lesion of  5 cm, and
(ii) Child–Pugh class A or B cirrhosis. The two groups were com-
pared on the primary endpoint of overall survival. Comparison
was carried out in an intention-to-treat fashion16 considering time
zero as the date of resection or date of listing for transplantation.
Patient outcomes were collected during August 2011.
Diagnosis
Hepatitis C virus infection was documented by anti-HCV serol-
ogy or evidence of HCV RNA by polymerase chain reaction analy-
sis. The diagnosis of HCC was based on at least one cross-sectional
imaging study [computed tomography (CT) or magnetic reso-
nance imaging (MRI)] showing the characteristic vascular
enhancement pattern.26 Chest scans by CT were performed rou-
tinely to rule out pulmonary metastases. Pathological confirma-
tion of HCC was ultimately obtained for patients who underwent
resection or transplantation.
Resection as primary treatment
Patients with solitary HCC without evidence of extrahepatic
spread on imaging and with Child–Pugh class A cirrhosis and no
clinical or radiographic evidence of portal hypertension were con-
sidered for partial hepatectomy.
Resection commenced with intraoperative ultrasound exami-
nation of the entire liver to assess the extent of the main tumour
and search for additional tumours. Surgery was performed using
low central venous pressure anaesthesia and intermittent inflow
occlusion (Pringle manoeuvre).3
Surveillance following resection consisted of the monitoring of
serum alpha-fetoprotein (AFP) levels and CT (or MRI) scans of
the chest and abdomen every 3 months during the first year, every
4 months during the second year, and biannually thereafter. Soli-
tary intrahepatic recurrence was treated with repeat resection pro-
vided liver function remained preserved. Solitary pulmonary or
intra-abdominal recurrences were also preferentially resected.
Resected patients with multinodular intrahepatic recurrence or
with compromised liver function were treated with radiofre-
quency ablation (RFA) or transarterial chemoembolization
(TACE) depending on the sizes and number of recurrent tumours;
patients in this group without prohibitive comorbidities were also
referred for salvage transplant evaluation. From 2008, patients
with recurrence who were not eligible for a curative treatment
were treated with sorafenib.
Transplant listing as primary treatment
Patients with HCC were placed on the transplant waiting list when
impaired liver function or oligonodularity precluded resection.
Patients with radiographic evidence of gross vascular invasion
were not listed. Patients with tumours that fell within the Milan
Criteria11 (one tumour measuring 5 cm or up to three tumours
all of < 3 cm in size) were accorded tumour-related priority
according to the policy of the United Network for Organ Sharing
(UNOS).27 In this study, only data for patients with solitary HCC
lesions of  5 cm were analysed. Marginal grafts (such as those
from donors aged > 65 years, non-beating heart donors, donors
with multiple comorbidities and HCV-positive donors, and grafts
with hepatic macrosteatosis of > 10% or cold ischaemic time of
> 10 h) were generally not used in this population. Listed patients
who developed gross vascular invasion, tumour progression
outside the Milan Criteria or prohibitive comorbidities were
removed from the list. Patients who received transplants from
living donors were not excluded from this study.
Post-transplant immunosuppression consisted of tacrolimus,
mycophenolate mofetil and corticosteroid. Surveillance of HCC
following transplantation consisted of the monitoring of serum
AFP and CT (or MRI) scans of the chest and abdomen every
3 months in the first year, every 6 months in the second year, and
yearly thereafter until year 5.
Prognostic variables
Variables collected and analysed included age, gender, race,
albumin, total bilirubin, creatinine, international normalized
ratio (INR), platelets, Child–Pugh class, calculated Model for End-
stage Liver Disease (MELD) score, AFP, radiographic tumour size,
waiting list exclusion, pathological tumour size and number,
microscopic and gross vascular invasion, satellite nodules, tumour
grade, UNOS modified tumour–node–metastasis (TNM) stage,27
American Joint Committee on Cancer (AJCC) pathological TNM
stage,28 and primary treatment modality (i.e. resection vs. trans-
plant listing).
Statistical analysis
Categorical variables were expressed as valid percentages and
compared using the chi-squared test or Fisher’s exact test as
appropriate. Continuous variables were expressed as the mean 
standard deviation and compared using Student’s t-test; alterna-
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tively, they were expressed as the median and range and compared
using the Mann–Whitney test. Survival and recurrence were esti-
mated using the Kaplan–Meier method and groups were com-
pared using the log-rank test. Those patients receiving salvage LT
were censored on the date of death or last follow-up for the
survival analyses in this study. Univariate analyses were performed
to determine which clinical and pathological variables were asso-
ciated with increased recurrence and impaired survival. Factors
deemed significant on univariate analysis were entered into a mul-
tivariate analysis based on the Cox regression model. Continuous
variables were dichotomized at the median value or using cut-offs
determined by receiver operator characteristic analyses. P-values
of < 0.05 were considered to indicate statistical significance.
Analysis was carried out using spss Version 18.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
A total of 271 consecutive patients with documented primary
HCV-HCC were treated with resection (n = 93) or placed on the
transplant waiting list (n = 178) at Mount Sinai Medical Center. Of
these 271 patients, 135 fulfilled the aforementioned criteria of a
single HCC of  5 cm at initial diagnosis and Child–Pugh class A
or B cirrhosis; four of these patients were excluded because ulti-
mate pathological analysis revealed a non-HCC tumour. The
present study group comprised the remaining 131 patients, who
were divided according to whether they underwent liver resection
(the LR group, n = 56) or were listed for LT (the LT-listed group,
n = 75). A comparison of the demographic and clinical data is
presented in Table 1.
Transplant waiting list
Median waiting time on the transplant list was 5.7 months (range:
0.1–44.6 months). Of the 75 LT-listed patients, 59 (78.7%)
received one or more pre-transplant locoregional therapies (mean
of 1.80  0.94 treatments each) to prevent tumour progression.
These included: TACE (n = 28); RFA (n = 15); percutaneous
ethanol ablation (PEI) (n = 3), and a combination of TACE and
RFA/PEI (n = 13). Fifty-two (69.3%) patients underwent LT; the
remaining 23 patients were either removed from the waiting list
(n = 13) or died while listed (n = 10). Causes of removal from the
waiting list were tumour progression (n = 8), non-compliance
(n = 2) and complete response to neoadjuvant treatment (n = 3).
Causes of death while on the waiting list were hepatic decompen-
sation (n = 3), sepsis (n = 2), respiratory failure (n = 1), compli-
Table 1 Clinical and demographic data for patients with hepatitis C-associated hepatocellular carcinoma listed for liver transplantation
(LT-listed) or treated with liver resection (LR)
LT-listed group (n = 75) LR group(n = 56) P-value
Age, years, mean  SD 57.4  6.3 60.7  8.8 0.020
Male gender, n (%) 60 (80.0) 41 (73.2) 0.361
Hepatitis B virus co-infection, n (%) 1 (1.3) 1 (1.8) 0.891
Alcoholic liver disease, n (%) 15 (20.0) 3 (5.4) 0.020
Ethnicity, n (%)
White 39 (52.0) 24 (42.9) 0.051
African-American 12 (16.0) 13 (23.2)
Hispanic 21 (28.0) 10 (17.9)
Asian 1 (1.3) 7 (12.5)
Other 2 (2.7) 2 (3.6)
Child–Pugh class, n (%)
A 28 (37.3) 55 (98.2) < 0.001
B 47 (62.7) 1 (1.8)
C 0 0
Calculated MELD score, mean  SD 12.1  3.8 7.8  1.9 < 0.001
Bilirubin, mg/dl, mean  SD 2.32  3.59 0.66  0.25 0.001
Albumin, g/dl, mean  SD 3.14  0.52 3.93  0.50 < 0.001
INR, mean  SD 1.35  0.25 1.08  0.14 < 0.001
Creatinine, mg/dl, mean  SD 0.88  0.25 0.89  0.33 0.747
Platelets  100 000/ml, n (%) 24 (32.0) 48 (85.7) < 0.001
Median AFP, ng/ml, median (range) 10.5 (2.2–6301.0) 21.0 (2.5–5312.6) 0.011
Radiographic tumour sizea, cm, mean  SD 2.28  1.03 3.13  1.08 < 0.001
aMeasured at time of listing or resection.
SD, standard deviation; MELD, Model for End-stage Liver Disease; INR, international normalized ratio; AFP, alpha-fetoprotein.
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cations of myasthenia gravis (n = 1) and subdural haematoma
(n = 1). The cause of death was unknown in two patients.
Perioperative and pathological data
All 52 transplants were performed using organs procured from
deceased donors, three of which were partial livers (all right lobe).
The average donor age was 51.6  17.1 years. Mortality within
90 days of transplant was observed in five (9.6%) patients. The
causes of death were primary graft non-function (n = 1), biliary
sepsis (n = 1), aspiration (n = 1), aplastic anaemia (n = 1) and
graft-vs.-host disease (n = 1).
Of the 56 resections performed, 31 (55.4%) were non-
anatomic; the remaining 25 (44.6%) procedures were anatomic
resections, specifically: segmentectomy (n = 8); bisegmentectomy
(n = 11); left lobectomy (n = 3); right lobectomy (n = 2), and
central hepatectomy (n = 1). Mortality within 90 days of resection
was observed in two (3.6%) patients secondary to intestinal inf-
arction and aspiration, respectively.
Pathological data for the two groups are compared in Table 2.
Longterm outcomes: LT-listed group
Median follow-up in the LT-listed group was 30.1 months (range:
0.0–108.7 months). Survivors were followed for a median of
74.3 months (range: 1.4–108.7 months). Of the 52 patients trans-
planted, tumour recurrence was observed in 12 (23.1%) cases.
Actuarial 5-year recurrence following transplant was 30.5%; the
corresponding median time to recurrence was not reached.
At the time of final analysis, 44 patients had died, including the
19 patients who did not undergo transplantation. Of the 25
patients who died following transplantation, five succumbed to
hepatic decompensation from HCV-associated graft cirrhosis and
four of these died within 24 months of transplant. Another nine
patients died of recurrent tumour. Intention-to-treat survival
rates at 1, 3 and 5 years from the date of listing were 74.3%, 48.6%
and 44.1%, respectively; the corresponding median  standard
error (SE) intention-to-treat survival was 30.6  16.6 months. In
the 52 patients who underwent LT, survival rates at 1, 3 and 5 years
from the date of transplantation were 75.0%, 59.4% and 51.3%,
respectively; the corresponding median survival was 62.7 months.
Longterm outcomes: LR group
Median follow-up in the LR group was 46.6 months (range:
0.1–101.0 months). Survivors were followed for a median of
58.3 months (range: 0.4–101.1 months). Tumour recurrence was
observed in 34 (60.7%) patients. Actuarial 5-year recurrence fol-
lowing resection was 71.5%; the corresponding median SE time
to recurrence was 27.3  5.0 months. Recurrence was solely int-
rahepatic in 32 of 34 patients. Twenty-nine of these 32 patients
were treated for recurrence with the following modalities: salvage
LT (n = 11); RFA (n = 7); repeat resection (n = 6), and TACE
(n = 5). Recurrence in the LR group is compared with that in the
52 patients who received primary transplantations in Fig. 1.
At the time of final analysis, there had been 29 deaths, 14 of
which were secondary to recurrent HCC. Survival rates at 1, 3 and
5 years from the date of resection were 85.1%, 65.4% and 51.6%,
respectively; the corresponding median SE survival was 61.8
9.8 months. Median  SE survival following treatment of recur-
rence (n = 23) was 27.5 3.1 months. Intention-to-treat survival
rates in the two groups are compared in Fig. 2; a clear trend
favouring resection over listing for LT is demonstrated. This
finding persisted despite stratification of the cohort to those
treated before and after each of the three dates on which UNOS
modified the allocation of MELD exception points (February
2003, April 2004, March 2005)27 (curves not shown). Post-surgical
survival in the LR group is compared with that in the 52 patients
primarily transplanted in Fig. 3.
Prognostic factors: survival
For the entire cohort, factors associated with inferior survival on
univariate analysis are presented in Table 3. Of note, primary
Table 2 Pathological data for patients with hepatitis C-associated









3.30  1.86 3.35  1.31 0.871
Tumour number, n (%)
Solitary 27 (51.9) 49 (89.1) < 0.001
Multinodular 25 (48.1) 6 (10.9)
Vascular invasion, n (%)
None 30 (57.7) 22 (40.0) 0.120
Microscopic 19 (36.5) 25 (45.5)
Gross 3 (5.8) 8 (14.5)
Satellite nodules, n (%) 7 (13.5) 12 (21.8) 0.258
Differentiation, n (%)
Good 17 (32.7) 15 (27.3) 0.156
Moderate 22 (42.3) 28 (50.9)
Poor 7 (13.5) 11 (20.0)
Necrotic (treated) 6 (11.5) 1 (1.8)
AJCC TNM stagea, n (%)
I 14 (26.9) 19 (34.5) 0.451
II 32 (61.5) 28 (50.9)
III 5 (9.6) 8 (14.5)
IV 1 (1.9) 0
UNOS TNM stagea, n (%)
I 6 (11.5) 3 (5.5) 0.201
II 27 (51.9) 39 (70.9)
III 8 (15.4) 4 (7.3)
IV 11 (21.2) 9 (16.4) 0.871
aBased on pathological analysis.
SD, standard deviation; AJCC, American Joint Committee on Cancer;
TNM, tumour–node–metastasis; UNOS, United Network for Organ
Sharing.
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treatment modality (resection vs. LT listing) was not a significant
factor on univariate analysis. The following factors retained sig-
nificance as independent predictors on multivariate analysis:
radiographic tumour size of > 2.5 cm [hazard ratio (HR) 2.25,
Figure 1 Recurrence rates in resected patients (n = 56) and trans-
planted patients (n = 52); P < 0.001. LR, liver resection; LT, liver
transplant
Figure 2 Intention-to-treat survival in resected patients (n = 56) vs.
patients listed for transplant (n = 75); P = 0.311. LR, liver resection;
LT-listed, liver transplant-listed
Figure 3 Post-surgical survival in resected patients (n = 56) vs. trans-
planted patients (n = 52); P = 0.244. LR, liver resection; LT, liver
transplant
Table 3 Univariate analysis of factors for survival in patients with
hepatitis C-associated hepatocellular carcinoma who were resected








 2.5 cm 77 (58.8) 92.2  18.0 0.006a 56.7
> 2.5 cm 54 (41.2) 27.1  8.3 34.2
Albumin level
 3.5 gm/dl 75 (57.3) 20.7  6.4 0.002a 32.8
> 3.5 gm/dl 56 (42.7) 92.1  21.1 65.0
INR level
 1.2 79 (60.3) 68.7  14.7 0.009 49.5
> 1.2 52 (39.7) 20.7  7.5 30.8
MELD score
 9.0 63 (48.1) 68.7  14.3 0.027 59.5
> 9.0 68 (51.9) 24.7  7.5 36.3
aRetained significance in multivariate analysis.
INR, international normalized ratio; MELD, Model for End-stage Liver
Disease; SEM, standard error of the mean.
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95% confidence interval (CI) 1.36–3.70; P = 0.001] and albumin
 3.5 g/dl (HR 2.07, 95% CI 1.08–4.00; P = 0.03).
Prognostic factors: recurrence
For the entire cohort (excluding patients listed for but not receiv-
ing LT), factors associated with increased recurrence on univariate
analysis are presented in Table 4. On multivariate analysis, only
vascular invasion (microscopic or gross) retained significance as
an independent predictor (HR 3.86, 95% CI 1.91–7.79; P < 0.001).
Child–Pugh class A cirrhosis subgroup comparison
An intention-to-treat survival comparison of Child–Pugh class A
patients is presented in Fig. 4. There was no significant difference
in intention-to-treat survival between the 28 patients listed for
transplant (median survival 63.8  15.0 months) and the 55
patients resected (median survival 61.9  9.5 months).
Discussion
Partial hepatectomy and LT are competing potentially curative
treatments for early-stage HCC. Underlying HCV infection intro-
duces an additional layer of complexity to patient management
and has a strong influence on outcomes. A single-institution
intention-to-treat comparison of these two primary approaches is
the focus of this report.
Similarly to previous studies,14,16,29 this analysis demonstrated
no significant survival difference between transplantation and
resection; median and 5-year survival were essentially equivalent
in patients undergoing resection and those undergoing LT.
However, there was a clear trend favouring resection over trans-
plant from an intention-to-treat perspective. The basis for this
trend is the 30% rate of dropout from the waiting list, which
leads to an early decline in the survival curve for LT-listed
patients. Shah et al.29 showed a 21% dropout rate after a median
waiting list time of 7.7 months; the rate identified in the present
study was less encouraging despite a shorter waiting time
(5.7 months) and the liberal use of preoperative locoregional
therapies. Tumour-related exclusion accounted for only part of
this deficit; a significant proportion of the present patients died
while awaiting transplant as a result of a variety of medical
causes including hepatic decompensation. Liver injury from
locoregional treatment may have been a contributing factor in
these cases of hepatic decompensation.
Early post-transplant mortality from sepsis and
immunosuppression-related haematologic disorders also contrib-
Table 4 Univariate analysis of factors associated with recurrence in
patients with hepatitis C-associated hepatocellular carcinoma








Liver transplant 52 Not reached < 0.001 30.5
Liver resection 56 27.3  5.0 71.5
AFP level
 10 mg/dl 44 99.6  NA < 0.001 28.2
> 10 mg/dl 64 25.9  5.4 69.1
Pathological tumour size
 3 cm 58 99.6  43.1 0.012 44.0
> 3 cm 49 25.9  10.2 63.2
Vascular invasiona
Present 55 17.7  5.4 < 0.001b 87.5
Absent 52 Not reached 27.8
Tumour grade
Good 32 99.6  13.0 0.005 30.1
Moderate–poor 68 27.3  9.3 76.8
Satellites
Present 19 14.0  2.2 < 0.001 92.0
Absent 88 99.6  32.8 44.4
AJCC TNM staging
I 33 85.1  NA 0.016 38.9
II 60 47.6  15.8 55.0
III 13 14.5  5.5 79.8
IV 1 – –
aMicroscopic or gross.
bRetained significance in multivariate analysis.
AFP level, alpha-fetoprotein level; AJCC, American Joint Committee
on Cancer; NA, not available; SEM, standard error of the mean; TNM,
tumour–node–metastasis.
Figure 4 Intention-to-treat survival in patients with Child–Pugh class
A cirrhosis who underwent resection (n = 55) or who were listed for
transplant (n = 28); P = 795. LR, liver resection; LT-listed, liver
transplant-listed
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uted to the early divergence of the intention-to-treat (and post-
surgical) survival curves in favour of the LR group. In addition,
accelerated HCV-related graft cirrhosis and ultimate hepatic
decompensation led to death in four LT patients. The rate at which
HCV-associated graft failure was observed in the present study
was similar to those reported in other transplant series,30–32 and
underscores the relevance of this problem in the HCV-infected
transplant population as a whole.
With regard to recurrence, the high 5-year recurrence rate
(71.5%) following resection is in line with those cited in previous
reports describing the resection of small HCV-associated
HCC,6,20,21 and recurrence was the most frequent cause of death in
the LR group. The emergence of vascular invasion as an independ-
ent predictor for recurrence in the present cohort was also con-
sistent with previous reports describing outcomes of resection as
well as those of transplant,8,9,13,15,20,30 and was associated in the
present LR group with early (within the first 2 years) intrahepatic
recurrence. Later intrahepatic recurrence was also common in the
LR group and was presumably related to de novo carcinogenesis.33
Regardless of their aetiopathogenesis, the overwhelming majority
of recurrences following resection were intrahepatic. Accordingly,
a large proportion of these recurrences (> 90%) were amenable to
curative treatments including RFA, repeat resection and salvage
LT, and an additional median survival from the date of recurrence
of 27.5 months was achieved. The present study group has previ-
ously shown that repeat resection for recurrence provides an addi-
tional median survival of 59 months.34
By contrast, the 5-year recurrence rate of 30.5% following trans-
plant was much higher than expected. With the use of the Milan
Criteria,11 most groups5,14,15,29 have reported rates of post-
transplant HCC recurrence lower than those observed here,
including in reports focused solely on HCC arising in the context
of HCV infection.12,30,31,35 It is likely that the high prevalence of
vascular invasion in the transplanted patients (42.3%) in the
present series underlies this high rate of recurrence; other
transplant series in which the Milan Criteria have been employed
for case selection have reported rates of vascular invasion of
6–20%.5,15,29,36 Although the present study group has previously
reported a higher incidence of vascular invasion in HCV-HCC than
in hepatitis B-associated HCC,37 other series specifically reporting
on transplant outcomes in HCV-HCC have noted lower rates of
vascular invasion than that observed in the current series.30,31,35
Vascular invasion is an aspect of the natural progression of HCC
over time. Patients in the present series were maintained within the
Milan Criteria over extended waiting periods by the application of
locoregional treatments and although progression as judged by
imaging may not have been observed in those patients who reached
transplant, progression in terms of vascular invasion may have
nonetheless occurred in a proportion of patients.
The aim of this study was to compare resection and transplan-
tation as competing alternatives for the primary treatment of
HCV-HCC. The study population was therefore limited to HCC
patients who could reasonably be treated with either modality:
they were required to exhibit a solitary HCC lesion measuring
 5 cm because multinodularity is a well-recognized predictor of
poor outcome after resection and because waiting list priority for
the receipt of a donor organ is unavailable to patients with HCC of
> 5 cm in size. Patients with Child–Pugh class A or B cirrhosis
were included. There is clearly an imbalance between the LR and
LT-listed groups in this regard: only patients with Child–Pugh
class A cirrhosis and no portal hypertension were submitted to
resection, whereas patients with portal hypertension or with
Child–Pugh class B cirrhosis were listed for transplant. Although
the present authors attempted to lessen this imbalance by making
a Child–Pugh class A subgroup comparison, inequity persists.
This flaw can only be truly overcome in a randomized trial.
Neither resection nor transplant is an optimal treatment for
HCV-HCC. Resected patients are plagued by a high incidence of
tumour recurrence and resection is applicable in only a minority
of patients. Conversely, transplant results are dependent on organ
availability, and even those patients fortunate enough to receive a
donor liver in the present series were no more likely to survive
than appropriate candidates who underwent resection, largely as a
result of the impact of HCV recurrence. This survival comparison
does, however, require cautious interpretation, given the afore-
mentioned differences in baseline liver function between the two
groups and the unfortunately high prevalence of vascular invasion
in transplanted patients. Nevertheless, in a setting of donor organ
scarcity, the present authors believe that these data support resec-
tion as a safe and reasonable option for patients with single HCC
lesions of  5 cm against a background of Child–Pugh class A
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